Sign inJoin waitlistJoin the waitlist

SW

Stephen Walsh

Physician · Brigham and Women's Hospital

Credentials: · · ·

History

Brigham and Women's Hospital
Present

Infectious Disease
Brigham and Women's Hospital
2002–2004
Internal Medicine
Boston Medical Center
1998–2001
MCGILL UNIV, MONTREAL
1994–1998

Research

A Bivalent Omicron-Containing Booster Vaccine against Covid-19
New England Journal of Medicine · 2022 · 518 citations
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
Systematic review or meta-analysis · Nature Communications · 2021 · 221 citations
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind,…
The Lancet · 2018 · 163 citations

Lindsey Baden
48 papers
Lawrence Corey
18 papers
Paul Goepfert
17 papers
Dan Barouch
16 papers
Juliana McElrath
14 papers
Kathryn Stephenson
13 papers
NR
Nadine Rouphael
13 papers
Magdalena Sobieszczyk
12 papers
RD
Raphael Dolin
12 papers
Jim Kublin
11 papers
Kathleen Neuzil
11 papers
AS
Amy Sherman
9 papers · 1 as a fellow

Grants

Dermatotropic Cellular Immune Responses Induced by a Novel Smallpox Vaccine
National Institute of Allergy and Infectious Diseases · K23
Contact PI · $644.7K · Beth Israel Deaconess Medical Center
2010–2016
New England Primate Research Center Base Grant
National Center for Research Resources · P51
Project lead · $721.2K · Harvard Medical School
2006–2011

Clinical trials

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults
Principal investigator · Not yet recruiting · Phase 2
Worcester HIV Vaccine
2026–2029
Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants
Study chair · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2019–2020
Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults
Study chair · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2018–2020